378 related articles for article (PubMed ID: 34895759)
1. From cardio-oncology to cardio-onco-pharmacology: Towards a multidisciplinary approach in the understanding and management of cardiotoxicity.
Ederhy S; Devos P; Cohen A; Pinna B; Bretagne M; Nguyen LS; Salem JE
Therapie; 2022; 77(2):197-206. PubMed ID: 34895759
[TBL] [Abstract][Full Text] [Related]
2. Interactions between cardiology and oncology drugs in precision cardio-oncology.
Kamaraju S; Mohan M; Zaharova S; Wallace B; McGraw J; Lokken J; Tierney J; Weil E; Fatunde O; Brown SA
Clin Sci (Lond); 2021 Jun; 135(11):1333-1351. PubMed ID: 34076246
[TBL] [Abstract][Full Text] [Related]
3. The Role of CYP450 Drug Metabolism in Precision Cardio-Oncology.
Fatunde OA; Brown SA
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963461
[TBL] [Abstract][Full Text] [Related]
4. Cardiorenal Impact of Anti-Cancer Agents: The Intersection of Onco-Nephrology and Cardio-Oncology.
Attieh RM; Nunez B; Copeland-Halperin RS; Jhaveri KD
Cardiorenal Med; 2024; 14(1):281-293. PubMed ID: 38684145
[TBL] [Abstract][Full Text] [Related]
5. Strategies to Prevent Cardiotoxicity.
Graffagnino J; Kondapalli L; Arora G; Hawi R; Lenneman CG
Curr Treat Options Oncol; 2020 Apr; 21(4):32. PubMed ID: 32270293
[TBL] [Abstract][Full Text] [Related]
6. Cardio-oncology: a multidisciplinary approach for detection, prevention and management of cardiac dysfunction in cancer patients.
Tajiri K; Aonuma K; Sekine I
Jpn J Clin Oncol; 2017 Aug; 47(8):678-682. PubMed ID: 28505345
[TBL] [Abstract][Full Text] [Related]
7. Cardio-Oncology: Mechanisms, Drug Combinations, and Reverse Cardio-Oncology.
Liang Z; He Y; Hu X
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142538
[TBL] [Abstract][Full Text] [Related]
8. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management.
Curigliano G; Cardinale D; Dent S; Criscitiello C; Aseyev O; Lenihan D; Cipolla CM
CA Cancer J Clin; 2016 Jul; 66(4):309-25. PubMed ID: 26919165
[TBL] [Abstract][Full Text] [Related]
9. Age-Related Considerations in Cardio-Oncology.
Screever EM; Meijers WC; Moslehi JJ
J Cardiovasc Pharmacol Ther; 2021 Mar; 26(2):103-113. PubMed ID: 33124480
[TBL] [Abstract][Full Text] [Related]
10. [Cardiotoxicity of anticancer therapies. Towards the implementation of cardio-oncology units].
Hameau R; Gabrielli L; Garrido M; Guzmán AM; Retamal I; Vacarezza MJ; Greig D; Ocqueteau M; Sánchez C; Pizarro M; Corvalán A; Lavandero S; Castro PF; Martínez G
Rev Med Chil; 2018 Jan; 146(1):68-77. PubMed ID: 29806680
[TBL] [Abstract][Full Text] [Related]
11. Cardio-Oncology-Beyond Anthracyclines and Ejection Fraction.
Geenty PD; Gregory AT; Nolan M; Denniss AR; Pepe S; Sverdlov AL; Thomas L
Heart Lung Circ; 2024 May; 33(5):547-552. PubMed ID: 38823894
[No Abstract] [Full Text] [Related]
12. Non-coding RNAs, cancer treatment and cardiotoxicity: A triad of new hope.
Mittal R; Krishnan M P S; Saxena R; Sampath A; Goyal B
Cancer Treat Res Commun; 2023; 36():100750. PubMed ID: 37531735
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological foundations of cardio-oncology.
Minotti G; Salvatorelli E; Menna P
J Pharmacol Exp Ther; 2010 Jul; 334(1):2-8. PubMed ID: 20335321
[TBL] [Abstract][Full Text] [Related]
14. What Does a Cardio-oncology Service Offer to the Oncologist and the Haematologist?
Andres MS; Pan J; Lyon AR
Clin Oncol (R Coll Radiol); 2021 Aug; 33(8):483-493. PubMed ID: 33832839
[TBL] [Abstract][Full Text] [Related]
15. Cardio-oncology - strategies for management of cancer-therapy related cardiovascular disease.
Totzeck M; Schuler M; Stuschke M; Heusch G; Rassaf T
Int J Cardiol; 2019 Apr; 280():163-175. PubMed ID: 30661849
[TBL] [Abstract][Full Text] [Related]
16. Organization and implementation of a cardio-oncology program.
Fiuza M; Ribeiro L; Magalhães A; Sousa AR; Nobre Menezes M; Jorge M; Costa L; Pinto FJ
Rev Port Cardiol; 2016 Sep; 35(9):485-94. PubMed ID: 27503589
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular toxicity of anticancer-targeted therapy: emerging issues in the era of cardio-oncology.
Raschi E; De Ponti F
Intern Emerg Med; 2012 Apr; 7(2):113-31. PubMed ID: 22161318
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular Toxicity and Risk Mitigation with Lung Cancer Treatment.
Yegya-Raman N; Berlin E; Feigenberg SJ; Ky B; Sun L
Curr Oncol Rep; 2023 May; 25(5):433-444. PubMed ID: 36811807
[TBL] [Abstract][Full Text] [Related]
19. Cardiotoxicity of Agents Used in Patients With Breast Cancer.
Zagami P; Trapani D; Nicolò E; Corti C; Valenza C; Criscitiello C; Curigliano G; Carey LA
JCO Oncol Pract; 2024 Jan; 20(1):38-46. PubMed ID: 37983586
[TBL] [Abstract][Full Text] [Related]
20. Modeling Precision Cardio-Oncology: Using Human-Induced Pluripotent Stem Cells for Risk Stratification and Prevention.
Perry TR; Roberts ML; Sunkara B; Maddula R; McLeish T; Gomez J; Lucas J; Rayan D; Patel S; Liang M; Bosnjak ZJ; Brown SA
Curr Oncol Rep; 2021 May; 23(7):77. PubMed ID: 33937943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
